# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
The company announced a CEO succession plan effective August 1, 2024, under which Paul R. Edick will be retiring from his day-t...
HC Wainwright & Co. analyst Oren Livnat reiterates Xeris Biopharma Holdings (NASDAQ:XERS) with a Buy and maintains $6 pr...
Participants who completed the study rated higher treatment satisfaction with XP-8121 compared to oral and a majority (72%) ind...
Piper Sandler analyst David Amsellem reiterates Xeris Biopharma Holdings (NASDAQ:XERS) with a Overweight and lowers the pric...
Xeris Biopharma Holdings (NASDAQ:XERS) reported quarterly losses of $(0.14) per share which missed the analyst consensus estima...